newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is the next evolution of inflammasome